MHRA (UK) approves Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) in newborns and infants – Merck
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns… read more.
